Debt-to-Equity Ratio

Bio-Techne Corporation’s debt-to-equity ratio of 0.10x means the company uses very little debt relative to shareholder equity, indicating a conservative financing approach with low financial leverage.

For a non-expert investor, this metric measures how much of the company’s operations are funded by borrowed money versus investor capital. Compared to sector peers, this ratio is well below the healthcare sector median of 0.46x, placing Bio-Techne in the 38th percentile — meaning it has less debt than 62% of its competitors. The year-over-year and quarter-over-quarter changes are both reported as N/A, so no trend direction is available for the last eight quarters. The combination of an exceptionally low debt level and the absence of any recent movement implies that financial risk from borrowing is minimal, but it also offers no insight into whether management is increasing or decreasing leverage. This metric supports the neutral verdict because the low ratio reduces downside risk from debt, yet the lack of trend data prevents it from strengthening or weakening the overall stock assessment.

Frequently Asked Questions

Closest Sector Peers